Distalmotion raises USD 90 million for its surgical robotWednesday 2 February 2022
Vaud-based medtech company Distalmotion has raised USD 90 million in a Series E financing round to support the global commercialization of its surgical robot Dexter.
Distalmotion’s CE-marked Dexter surgical robot shifts the paradigm of robotic surgery by bringing the surgeon back into the sterile field, allowing direct patient access at all times and integrating proven laparoscopic workflows into the robotic setup.
This novel user-centric approach makes the surgeon the focal point of the procedure, reducing complexity and delivering sought-after simplicity and versatility to the market for robotic surgery.
After making history at the Inselspital in Bern with the first clinical use of Distalmotion’s Dexter surgical robot in gynecology, the Lausanne-based company based has raised USD 90 million in a series E financing round led by Revival Healthcare Capital, with the participation of 415 CAPITAL, as well as existing investors.
“Dexter combines the best of both worlds – laparoscopy and robotics – to make sense of robotic surgery,” said Michael Friedrich, CEO of Distalmotion. “By addressing essential problems that operating room teams face, we can deliver on our mission to fast-track widespread adoption of robotic surgery in minimally invasive care. We are thrilled to have found the best-fitting partners to execute and deliver on this global purpose.”
The investment follows the successful completion of Dexter’s first clinical cases and aims to accelerate the Vaud-based company’s commercial scaling. Leading European hospitals are spearheading the development of procedural guidelines and training protocols for robotic surgery with Dexter as part of clinical studies and an Early Adopter Program (EAP). The company will also work closely with the U.S Food and Drug Administration (FDA) on a US submission supported by this financing.